OR WAIT null SECS
NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. The strategic partnership will lay the foundation for a new research entity to be established by the two companies. The transaction is expected to close mid 2020.
For more information, click here.